Multiple portion tablet
Patent 6663892 Issued on December 16, 2003. Estimated Expiration Date: 
August 19, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 19, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 701438 2888382 3048526 3125491 3358687 Enzyme-containing denture cleanser tablet Compressed and formed alkaline component suitable for use in buffered aspirin product Oral garlic preparations and process for preparing same Fibre formulations Sustained release pharmaceutical preparations containing an analgesic and a decongestant InventorAssigneeApplicationNo. 10/223127 filed on 08/19/2002US Classes:424/472, Layered unitary dosage forms424/464, Tablets, lozenges, or pills424/682, Aluminum, calcium or magnesium element, or compound containing424/686, Carbonate or bicarbonate424/687, Calcium carbonate424/688, Oxide or hydroxide424/689, With stabilizer or suspending agent424/690, Aluminum hydroxide424/692, Magnesium hydroxide or oxide424/715, Carbonate424/716, Ammonium carbonate424/717, Bicarbonate514/400At imidazole ring carbonExaminersPrimary: Page, Thurman K.Assistant: George, Konata M. Attorney, Agent or FirmInternational ClassesA61K 9/24 (20060101)A61K 45/06 (20060101) A61K 45/00 (20060101) AbstractA solid orally administrable pharmaceutical dosage form for the treatment of gastric disorders includes a first portion containing a therapeutically effective amount of a histamine H2 -receptor antagonist, and a second portion immediately adjacent the first portion without an intervening barrier disposed between the first portion and the second portion, the second portion containing a therapeutically effective amount of an antacid. Physical separation of the active ingredients into two different portions without a separating barrier has been found sufficient to prevent degradation of the histamine H2 -receptor antagonist due to contact with the antacid. The invention therefore provides stabilization of a histamine H2 -receptor antagonist-antacid combination tablet which is comparable to known multiple portion tablets, but without an intervening barrier between the antacid portion and the histamine H2 -receptor antagonist portion. Therefore, the benefits of the prior art are achieved at a reduced cost by eliminating a barrier and manufacturing steps associated with the provision of a barrier, as is conventional.Field of SearchPREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORMTablets, lozenges, or pills Layered unitary dosage forms Aluminum, calcium or magnesium element, or compound containing Carbonate or bicarbonate Calcium carbonate Oxide or hydroxide With stabilizer or suspending agent Aluminum hydroxide Magnesium hydroxide or oxide | |
